Rallybio received Nasdaq listing approval tied to its merger and set dates for its $13.90-per-share cash payment. The deal still depends on closing conditions, but the approval and scheduled payment favor holders.
Nasdaq's approval clears a listing step for the merger. The scheduled cash payment gives eligible holders a defined payout. The deal can still be delayed or fail if remaining closing conditions are not met.
Follow Rallybio Corp (RLYB) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for RLYB